Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drop T2769 takes on Hylo-Forte in dry eye showdown

NCT ID NCT06375499

Symptom relief Sponsor: Laboratoires Thea Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a new eye drop called T2769 works as well as a standard treatment (Hylo-Forte) for people with moderate to severe dry eye. 74 adults who still had dry eye symptoms despite using artificial tears took part. The main goal was to see if T2769 could reduce eye surface damage as effectively as Hylo-Forte over 36 days.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

74 people

The number who actually took part.

Started

Sep 2024

Finished

Jan 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Main Inclusion Criteria (At Screening visit): * Informed consent signed and dated (obtained prior to initiating any procedures). * Patient aged ≥18 years old. * Persistence of dry eye syndrome, despite artificial tears use in the previous month prior to the screening visit Main Exclusion Criteria (At both Screening and Randomisation visits): * Far Best-Corrected Visual Acuity (BCVA) ≥+0.7 LogMar (e.g., ≤0.2 in decimal value or ≤20/100 Snellen equivalent or ≤50 letters Early Treatment Diabetic Retinopathy Study (ETDRS)). * Patient with previous or current ophthalmic condition

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry eye syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dry eye syndrome

Contacts and locations

Locations

  • Axon Clinical, s.r.o.

    Prague, 15000, Czechia

  • Ermellek Egeszsegcentrum

    Létavértes, Hb, 4281, Hungary

  • Ganglion Medical Center

    Pécs, Baranya, 7621, Hungary

  • OFTEX, s.r.o.

    Prague, 11800, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.